| 33.66 -1.5 (-4.27%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 42.74 | 1-year : | 49.93 |
| Resists | First : | 36.59 | Second : | 42.74 |
| Pivot price | 34.49  |
|||
| Supports | First : | 32.82 |
Second : | 30.48 |
| MAs | MA(5) : | 34.67 |
MA(20) : | 34.15 |
| MA(100) : | 29.8 |
MA(250) : | 26.4 |
|
| MACD | MACD : | 0.8 |
Signal : | 1 |
| %K %D | K(14,3) : | 44.2 |
D(3) : | 55.1 |
| RSI | RSI(14): 50.8 |
|||
| 52-week | High : | 36.59 | Low : | 19.12 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHVS ] has closed above bottom band by 24.4%. Bollinger Bands are 10.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.26 - 35.44 | 35.44 - 35.58 |
| Low: | 32.75 - 32.98 | 32.98 - 33.17 |
| Close: | 33.34 - 33.69 | 33.69 - 33.97 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Wed, 15 Jul 2026
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance
Tue, 14 Jul 2026
Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event - Stock Titan
Tue, 14 Jul 2026
Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade - Zacks Investment Research
Mon, 13 Jul 2026
Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares - Stock Titan
Mon, 06 Jul 2026
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
Mon, 29 Jun 2026
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 986 (K) |
| Shares Short P.Month | 709 (K) |
| EPS | -3.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -73.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -147 (M) |
| Levered Free Cash Flow | -88 (M) |
| PE Ratio | -11.15 |
| PEG Ratio | 0 |
| Price to Book value | 8.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|